Oncodesign, a biopharmaceutical group that deals with precision medicine, in collaboration with UNICANCER unveiled details regarding the OncoSNIPE artificial intelligence project. Launched after receiving a financing grant of €7.7 million under the Investments for the Future Programme, the project is geared towards developing and applying artificial intelligence methods to cancer research. This funding propelled the OncoSNIPE’s aggregate budget to €12 million.
The effort by UNICANCER, a combination of 20 French Comprehensive Cancer Centers, to join the artificial intelligence project gives Oncodesign’s partners access to a digital 3.0 platform that is devoted to cancer dubbed ConSoRe. Thanks to the partnership, the platform will be considerably enriched by the OncoSNIPE partners through various ways like the creation of a link with tranSMART precision medicine platform, omic data integration from the clinical trial, anonymization of patient records and identification of patient populations resistant to cancer therapies among others.
Philippe Genne, the chief executive officer and founder of Oncodesign, cited that the OncoSNIPE artificial intelligence project aims to boost the resistance to cancer therapies. This effort relies on the contextualization of omics, imaging, and clinical data through improving relevant data derived from patient records. He also added that upon completion of the project, Oncodesign would have the ability to spot new targets to address various issues like unresponsiveness and resistance to treatment. Through both licensing and partnership programs, this achievement will make OncoSNIPE a potent catalyst for the group’s Discovery endeavors. Philippe Genne concluded by saying that this artificial intelligence technology is fundamental for precision medicine, which is an area that Oncodesign looks forward to expanding considerably in the future.
On the other hand, UNICANCER’s managing director, Pascale Flamant acknowledged the OncoSNIPE artificial intelligence project for being highly innovative and keeping its promise to provide better care for patients who are unresponsive or resistant to classical therapies. He also highlighted UNICANCER’ s delight in availing its ConSoRe tool to Oncodesign as well as plans to allow the installation of the tool in healthcare facilities as opposed to just comprehensive cancer centers.
Since the North-West IV ethics review board approved the Oncodesign’s artificial intelligence project, a longitudinal clinical trial can be conducted. The trial will enroll 600 patients in pancreatic cancer, breast cancer, and lung cancer, which make up the three cancer signs that represent the sources of both unresponsiveness and resistance to classical oncology therapies. In addition, the longitudinal trial will be devoted to studying molecular profiles that are related to unresponsiveness to cancer therapies in patients suffering from the three cancers.